下一代异形选择性纤维细胞生长因子受体抑制剂
1Chemical Biology Research Center, School of Pharmacy, Hangzhou Medical College, Hangzhou 310014, Zhejiang, China; Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.
Trends in pharmacological sciences
|October 22, 2025
概括
不调节的纤维细胞生长因子受体 (FGFR) 信号驱动癌症. 新的FGFR抑制剂提供了向治疗,克服了早期药物所见的耐药性和毒性问题.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 不调节的纤维细胞生长因子受体 (FGFR) 信号传递是各种癌症的关键驱动因素.
- 目前的泛FGFR抑制剂因耐药性和非标毒性而面临限制.
研究的目的:
- 审查目前针对FGFR的治疗方法.
- 评估下一代FGFR抑制剂和新的策略.
- 为了指导未来的FGFR向癌症治疗的研究.
主要方法:
- 对当前的FGFR抑制剂和临床发展的文献综述.
- 对新出现的FGFR异形选择性抑制剂,降解剂,抗体和蛋白质的分析.
- 评估与FGFR抑制相关的抵抗机制和毒性.
主要成果:
- 几种下一代FGFR抑制剂针对特定异型 (FGFR2,FGFR3,FGFR4) 正在临床开发中.
- 新的治疗策略包括降解剂,抗体和工程蛋白质正在出现.
- 与泛FGFR抑制剂相比,异形选择性旨在提高疗效并降低毒性.
结论:
- 下一代FGFR抑制剂和新的疗法显示出改善癌症治疗的前景.
- 解决目标耐药性和毒性对于治疗成功至关重要.
- 对异形选择性FGFR向的持续研究对于推进瘤疗法至关重要.
相关概念视频
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
TGF - β Signaling Pathway
10.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K
Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
Introduction to Fibroblasts
3.8K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.8K
Transducer Mechanism: G Protein–Coupled Receptors
4.0K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
4.0K


![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)